Eli Lilly and Co (LLY.US) seeks to expand the indications for its weight loss medication and will conduct trials to treat addictive behaviors.
Eli Lilly and Co will test a weight loss drug for treating addiction in 2025.
BofA Restarts Coverage of 11 Large-cap Biopharmas
Novo Nordisk's Wegovy Sales Drop Is Temporary; Forecasts Still on Track -- Market Talk
Jim Cramer Is 'Not A Fan' Of Novavax, Says This Tech Stock Is 'Expensive'
Eikonizo Therapeutics Announces Investment by Novo Nordisk; Advancing Lead Candidate EKZ-102 Toward Clinical Development
Express News | Novo Nordisk Says Investment Aimed At Expanding Enzymes Output Used For The Production Of Insulin, GLP-1 Medicines
